Showing 41 - 60 results of 30,689 for search '(( 100 we decrease ) OR ( 50 ((ms decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 0.79s Refine Results
  1. 41
  2. 42
  3. 43
  4. 44

    A Two-Year Randomized Trial of Interventions to Decrease Stress Hormone Vasopressin Production in Patients with Meniere’s Disease—A Pilot Study by Tadashi Kitahara (702040)

    Published 2016
    “…<div><p>Meniere's disease, a common inner ear condition, has an incidence of 15–50 per 100,000. …”
  5. 45
  6. 46

    RhpMS and DrmMS dose-response curves. by Megan Leander (459603)

    Published 2015
    “…<p>RhpMS dose dependently decreased <i>R</i>. <i>prolixus</i> cardiac contractility with an EC50 ∼ 140 nM. …”
  7. 47
  8. 48
  9. 49

    Data-Driven Tool for Cross-Run Ion Selection and Peak-Picking in Quantitative Proteomics with Data-Independent Acquisition LC–MS/MS by Binjun Yan (17310633)

    Published 2023
    “…Proteomics provides molecular bases of biology and disease, and liquid chromatography–tandem mass spectrometry (LC–MS/MS) is a platform widely used for bottom-up proteomics. …”
  10. 50
  11. 51

    Decreased Platelet Count in Patients Receiving Continuous Veno-Venous Hemofiltration: A Single-Center Retrospective Study by Buyun Wu (563610)

    Published 2014
    “…During the 3-day CVVH, 44.8% and 16% patients had a mild decline (20–49.9%) and severe decline (≥50%) in the platelet count,respectively; 37.6% and 16.0% patients had mild thrombocytopenia (platelet count 50.1–100×10<sup>9</sup>/L) and severe thrombocytopenia (platelet count ≤50×10<sup>9</sup>/L), respectively. …”
  12. 52
  13. 53
  14. 54

    Decrease in Vitamin D Status in the Greenlandic Adult Population from 1987–2010 by Nina O. Nielsen (490187)

    Published 2014
    “…</p><p>Conclusion</p><p>We identified a remarkable decrease in vitamin D status from 1987 to 2005–2010 and a presently low vitamin D status among Inuit in Greenland. …”
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  20. 60